IGF1 and neoplasm: In cases of complete resistance, both age-adjusted insulin-like growth factor I (IGF-I) and random GH (r-GH) levels remain elevated in the absence of a significant reduction of tumor volume (greater than or equal to 20%), even after 6 months of treatment with full-dose fg-SRL [8,10,11].